Epithalon
Epitalon — Tetrapeptide Telomere Regulator (AEDG)
PCAC voted 7–4 to recommend Epithalon for compounding — July 24, 2026
The FDA advisory committee recommended Epithalon for the 503A Bulks List, overriding FDA staff who opposed inclusion. The vote is not binding. Formal Category 1 placement requires rulemaking, typically 8 to 12 months. Epithalon was removed from Category 2 restrictions on April 23, 2026 and is not currently prohibited. Full registry
What is Epithalon?
Epithalon (also spelled Epitalon; sequence Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a polypeptide extract from the bovine pineal gland. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation developed it in the 1980s and have studied it for over 35 years. It is the most researched compound in the peptide bioregulator category.
Epithalon's primary proposed mechanism is activation of telomerase — the enzyme responsible for maintaining telomere length. Telomeres shorten with each cell division; Epithalon is proposed to slow or partially reverse this process. It also regulates melatonin production via the pineal gland, normalizes disrupted circadian rhythms in aging subjects, and demonstrates antioxidant and immune-modulating properties in animal models.
Research Evidence
Khavinson et al. (2003) demonstrated that Epithalon induces telomerase activity and telomere elongation in human fetal fibroblasts in vitro (PMID: 12937682). Russian human longevity trials report a 1.6 to 1.8-fold decrease in mortality over 6-year follow-up in elderly subjects treated with Epithalamin. Independent Western replication is absent.
Multiple rodent studies show reduced spontaneous tumor incidence and delayed carcinogenesis, including in HER-2/neu transgenic mice. Proposed mechanisms include DNA repair promotion and immune upregulation. No human cancer data exists.
Korkushko et al. documented restoration of disrupted nocturnal melatonin peaks in elderly human subjects following Epithalamin treatment. Consistent community reports of improved sleep quality align with the proposed pineal mechanism. Small study populations throughout.
Evidence grades: Gold = RCT human data · Silver = multiple animal or cohort studies, consistent · Bronze = limited or preliminary
Limitation: The majority of human research comes from a single group (Khavinson et al., St. Petersburg). Independent Western replication has not been published as of July 2026.
Dosing Protocols
Reconstitution Guide
| Vial Size | BAC Water | Concentration | 5 mg dose |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 100 units (1.0 mL) |
| 10 mg | 1 mL | 10 mg/mL | 50 units (0.5 mL) |
A 20-day course at 5 mg/day requires one 10 mg vial, reconstituted with 2 mL BAC water. Draw 100 units (1.0 mL) daily on a U-100 insulin syringe.
Frequently Asked Questions
What is the correct dose for Epithalon?
The dose established by Khavinson's clinical research is 5 to 10 mg per day by subcutaneous injection, run for 10 to 20 consecutive days per course, repeated 2 to 3 times per year. Some community protocols use 2 mg per day for 20 days as a lower-cost alternative. The 500 mcg to 1 mg range cited in some discussions has no published basis for subcutaneous use and is likely a confusion with intranasal delivery, where lower doses are used but with significantly lower bioavailability.
Does Epithalon lengthen telomeres?
In vitro studies show Epithalon activates telomerase in human somatic cells, associated with telomere elongation. Russian longevity studies report reduced age-related mortality in treated groups over 6 to 12 year follow-ups. The mechanism is biologically plausible, but the clinical magnitude in humans has not been confirmed by independent Western randomized controlled trials.
Why is Epithalon dosed in short cycles instead of daily?
Epithalon is a bioregulatory peptide. Khavinson's framework holds that it triggers regulatory cascades that persist after the peptide itself is cleared, so continuous daily use is unnecessary and the original protocols did not use it. The 10 to 20 day intensive cycle repeated 2 to 3 times per year replicates the clinical protocols from which all existing human data is derived. Continuous long-term daily use has not been studied.
Is 500 mcg or 1 mg of Epithalon enough?
No published research supports 500 mcg or 1 mg per day by subcutaneous injection as an effective Epithalon dose. The original Khavinson protocols and all subsequent documented community protocols use 2 mg at the low end, with 5 to 10 mg as the primary range. The 500 mcg figure likely originates from confusion with intranasal spray protocols or with much smaller animal-weight-adjusted doses. For subcutaneous injection, underdosing below 2 mg per day has no documented clinical basis.
How is Epithalon different from other longevity peptides?
Epithalon directly targets telomere biology via telomerase activation, which distinguishes it from other research longevity peptides. Thymosin Alpha-1 focuses on immune modulation. GHK-Cu targets collagen regeneration and wound healing. Epithalon is the only widely used research peptide with a proposed direct mechanism on cellular aging clocks. Its pulsed dosing model is also unique — most peptides are dosed daily or every other day continuously.
What is the regulatory status of Epithalon in 2026?
The FDA Pharmacy Compounding Advisory Committee voted 7 to 4 on July 24, 2026 to recommend Epithalon for the 503A Bulks List, which would allow compounding pharmacies to produce it for individual prescriptions. This recommendation is not binding. The FDA is not required to follow it, and formal Category 1 placement requires notice-and-comment rulemaking, typically 8 to 12 months. Epithalon was removed from the Category 2 restricted list on April 23, 2026 and is not currently prohibited from compounding, but the pharmacy pathway is not yet formally open.
References
- [1]Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis. Molecules. 2020;25(3):609.
- [2]Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682.
- [3]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. Core source for 5-10 mg/day cyclical protocols.
- [4]Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2004;125(8):539-548.
- [5]FDA Pharmacy Compounding Advisory Committee. Meeting transcript and vote records, July 23-24, 2026. Docket FDA-2025-N-6895.
Last updated: July 25, 2026. Profile prepared using primary source research from Khavinson et al., PCAC meeting records, and published dosing literature.
Share this article